ASRS 2024: Companies announce data presentations for event

News
Article

The ASRS annual meeting will take place in Stockholm, Sweden on July 16-20, 2024. Several major updates are already anticipated at the event.

(Image Credit: AdobeStock/Mistervlad)

(Image Credit: AdobeStock/Mistervlad)

The American Society of Retina Specialists (ASRS) is set to host their annual meeting in Stockholm, Sweden on July 16-20, 2024. This event brings together retina specialists from around the country and the globe to discuss the latest research, discuss clinical trials, and network with one another.

The meeting also serves as a launch for new data as companies relay results of new and ongoing studies. As ASRS 2024 draws nearer, companies in the retina space are beginning to highlight the presentations where they plan to showcase major news.

Below is a non-exhaustive list of companies and the information surrounding their ASRS presentations (in alphabetical order). Modern Retina will continue to highlight additional announcements as they are made.

4D Molecular Therapeutics

4D Molecular Therapeutics will present the initial interim 24-week landmark analysis from the population extension cohort of the PRISM Phase 2 Clinical Trial evaluating 4D-150. This potential treatment is being evaluated for a broad wet AMD patient population.1

The presentation entitled, “Phase 2 Population Extension Cohort in the PRISM Trial Evaluating 4D-150 in Adults with Neovascular Age-related Macular Degeneration” will take place Wednesday, July 17, 2024 at 8:49-8:53 am (CEST) and will be given by Raj K. Maturi, MD from Midwest Eye Institute & Retina Partners Midwest, Indianapolis, IN.1

Adverum Biotechnologies

Charles C. Wykoff, MD, PhD, FASRS, the Director of Research at Retina Consultants of Texas; Professor of Clinical Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, will present, “Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study.” This presentation will take place on Wednesday, July 17, 2024 at 8:45 am (CEST).2

References:
  1. 4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast. 4D Molecular Therapeutics. Published June 18, 2024. Accessed June 25, 2024. https://www.globenewswire.com/news-release/2024/06/18/2900361/0/en/4DMT-to-Present-Initial-Interim-24-week-Landmark-Analysis-from-the-4D-150-Phase-2-PRISM-Population-Extension-Cohort-in-a-Broad-Wet-AMD-Population-at-ASRS-and-Host-a-Corporate-Webca.html
  2. Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting. Adverum Biotechnologies, Inc. Published April 25, 2024. Accessed June 25, 2024. https://www.globenewswire.com/news-release/2024/04/25/2870046/32452/en/Adverum-Biotechnologies-to-Present-LUNA-26-week-Phase-2-Interim-Analysis-at-the-ASRS-Annual-Scientific-Meeting.html
Recent Videos
© 2024 MJH Life Sciences

All rights reserved.